10/05 Taiwan BIO Weekly
2026-10-05 |
| Taiwan BIO Weekly |
| Orient EuroPharma Expands Hyperhidrosis Drug Licensing Footprint, Partners with Japan's Maruho to Enter 10 ASEAN Markets 2 October, 2026 Orient EuroPharma (TW: 4120) announced a deepened strategic partnership with Maruho, a century-old Japanese dermatology pharmaceutical company, expanding the licensing scope for the hyperhidrosis treatment Rapifort from Taiwan to all 10 ASEAN member states, including Singapore, Malaysia, the Philippines, Indonesia, Thailand, and Vietnam. More... |
| PhytoHealth CEO Angel Lee Recognized for Driving the Advancement of World's First Prescription Drug for Cancer-Related Fatigue Press release 2 October, 2026 PhytoHealth Corporation (TW: 4108) CEO Angel Lee has been named one of Taiwan's 27th Ten Outstanding Young Women. The prestigious national recognition highlights her leadership in advancing PG2 Lyo. Injection--the world's first prescription drug approved specifically for moderate to severe cancer-related fatigue (CRF)--and her contributions to botanical drug development and cancer supportive care. More... |
| UnicoCell Biomed Secures First Cell Therapy Export License 2 October, 2026 UnicoCell Biomed (TW: 6794) announced that its proprietary human-derived allogeneic adipose-derived mesenchymal stem cell product, UC-hADSC, has received an export-only pharmaceutical license from Taiwan's Ministry of Health and Welfare (MOHW), license No. 000164. The company is the first in Taiwan's cell therapy industry to obtain an export license, paving the way for overseas market expansion and international partnerships. More... (in Chinese) |
| President Commends Taiwan BIO Award Winners, Calls for Continued Growth on Global Stage 1 October, 2026 Taiwan President Lai Ching-te met with winners of the 2026 Taiwan BIO Awards on the 1st of October, commending their long-term R&D investment and technological expertise for strengthening Taiwan's international competitiveness. Lai said the government will continue to support the industry through policy and regulatory measures, technology and funding as Taiwan works to strengthen its capabilities and industrial resilience. He expressed hope that more biomedical technologies and products will meet clinical needs, improve healthcare and quality of life, and help Taiwan expand its presence in the global biomedical industry. More... (in Chinese) |
| Bora Pharmaceuticals Sells Mesityl Drug License for US$30 Million 1 October, 2026 Bora Pharmaceuticals (TW: 6472) announced on the 30th of September that its board approved the sale by subsidiary Bora Biologics of the US and China drug approvals for Megestrol Acetate Oral Suspension, along with related rights worldwide except Hungary, to GENSCI Singapore, a subsidiary of Gensci Biotechnology, for US$30 million (approximately NT$950 million). Bora expects to recognize a US$30 million gain from the transaction, while a separate supply agreement will see Bora continue manufacturing the product, creating both one-time licensing income and long-term CDMO revenue. More... (in Chinese) |
| GlycoNex Partners with Japanese Firm to Tap Psoriasis Drug Market 1 October, 2026 GlycoNex (TW: 4168) announced on the 1st of October that it had signed a memorandum of understanding (MOU) with Japan's Mitsubishi Gas Chemical (MGC) to jointly launch development of their second biosimilar program. The two companies will build on their successful collaboration on SPD8 (denosumab), a biosimilar for osteoporosis, and work together on a new program targeting the global psoriasis drug market, which is worth tens of billions of dollars. More... (in Chinese) |
| Drug Approvals and Licensing Deals to Drive New Drug Stocks Through 2027 30 September, 2026 New drug stocks, seen as a major biotech market highlight in the fourth quarter, continue to benefit from a steady stream of positive developments. PharmaEssentia (TW: 6446), Lin BioScience (TW: 6696), Panion & BF Biotech (TW: 1760), TAHO Pharmaceuticals (TW: 6467) and Steminent Biotherapeutics (TW: 7729) have potential drug approval catalysts, while TLC BioSciences (TW: 7924), Obigen Pharma (TW: 7876), BRIM Biotechnology (TW: 6885) and Anxo Pharmaceutical (TW: 6677) stand to benefit from clinical trial readouts and licensing developments. Institutional investors expect the momentum from licensing deals and drug approvals to continue through 2027. More... (in Chinese) |
| Immunwork's Weight-Loss Drug TE-8105 Approved by Australia's HREC to Launch Phase IIb Trial 30 September, 2026 Immunwork, a subsidiary of T-E Pharma, announced on the 30th of September that its internally developed ultra-long-acting GLP-1 receptor agonist TE-8105 has received approval from Australia's Human Research Ethics Committee (HREC) to initiate a Phase IIb clinical trial. TE-8105 uses Immunwork's proprietary "Fatty Acid Bundle" platform, which combines modified GLP-1 with a fatty acid bundle containing two long-chain fatty acids. By enhancing the drug's binding to albumin, the technology is designed to extend TE-8105's duration of action in the body and potentially reduce dosing frequency. More... (in Chinese) |
| Novelwise Pharmaceutical Leverages AI for Drug Development Through Partnership with US Firm QuantHealth 29 September, 2026 Novelwise Pharmaceutical, a subsidiary of NatureWise Biotech & Medicals (TW: 4732), has partnered with US-based QuantHealth to use its AI-powered clinical trial simulation platform to support clinical development strategy planning and evaluation. Through the collaboration, Novelwise will leverage QuantHealth's computational capabilities and analytical tools to assess development options, challenge assumptions, explore alternatives, and make more informed use of research resources. The partnership is part of Novelwise's efforts to integrate AI into its drug research and development approach. More... (in Chinese) |
| TMU's Lee Yu-Ching Develops Next-Generation Antibody Platform, Wins Future Tech Award for Bispecific, Dual-Payload ADCs 29 September, 2026 In August, a team led by Lee Yu-Ching at Taipei Medical University (TMU) won the 2026 Future Tech Award for its "EE-CMab 2by2 ADC," which challenges the conventional antibody-drug conjugate (ADC) structure with a bispecific, dual-payload design. The technology was showcased as a featured innovation at the Future Tech Pavilion (FUTEX) of the 2026 Taiwan Innotech Expo, organized by Taiwan's National Science and Technology Council. According to official technology materials, the platform targets tumor heterogeneity and treatment-related resistance and has the potential to become a first-in-class next-generation ADC platform. More... (in Chinese) |
| PharmaEssentia Completes Acquisition of FormuRx Pharmaceuticals 29 September, 2026 PharmaEssentia (TW: 6446) announced on the 28th of September that it had completed the acquisition of all outstanding shares of FormuRx Pharmaceuticals, making the company a wholly owned subsidiary. PharmaEssentia said it will fully integrate FormuRx's core technology platforms, R&D equipment, and professional team to strengthen its capabilities in RNA therapeutics and in vivo chimeric antigen receptor T-cell (CAR-T) therapies, while accelerating related R&D programs. More... (in Chinese) |
| Oneness Biotech Advances SNS851 to Phase I Multiple-Ascending Dose Evaluation for Obesity-Associated Metabolic Diseases Press release 29 September, 2026 Oneness Biotech Co., Ltd. (TW: 4743), a Taiwan-based biotechnology company advancing innovative drugs for metabolic disorders, today announced completion of the single-ascending dose (SAD) portion (Part A) in healthy volunteers of its ongoing Phase I clinical trial evaluating SNS851 as a potential treatment for obesity-associated metabolic diseases. The study is advancing to the multiple-ascending dose (MAD) portion (Part B), which will evaluate repeat doses of SNS851 in participants with fatty liver disease. Data from the MAD portion are anticipated in the first quarter of 2027. More... |
| ========================================= |
| Please note that Taiwan BIO is not responsible for the accuracy of third-party news stories covered in this newsletter. |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2027 (27-31 July, 2027) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |